Alogliptin (Nesina) for type 2 diabetes

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1417, 2013, Pages 41-43

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; ALOGLIPTIN PLUS PIOGLITAZONE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; BLADDER CANCER; BONE DENSITY; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG APPROVAL; DRUG SAFETY; FRACTURE; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LETTER; LIFESTYLE MODIFICATION; LIVER FAILURE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; SIDE EFFECT; TASTE DISORDER; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; URACIL;

EID: 84878200007     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Drugs for type 2 diabetes. Treat Guidel Med Lett 2011; 9:47.
2. What comes after metformin for type 2 diabetes. Med Lett Drugs Ther 2012; 54:58.
3. MA Nauck et al. Efficacy and safety of adding the dipeptidyl peptidase- 4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebocontrolled study. Int J Clin Pract 2009; 63:46.
4. RA DeFronzo et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformintreated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:1615.
5. RE Pratley et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11:167.
6. RE Pratley et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009; 25:2361.
7. E Bosi et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011; 13:1088.
8. J Rosenstock et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009; 11:1145.
9. Linagliptin (Tradjenta) - a new DDP-4 inhibitor for type 2 diabetes. Med Lett Drugs Ther 2011; 53:49.
10. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85.
11. Sitagliptin (Januvia) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:1.
12. S Singh et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173:534.
13. PC Butler et al. A critical analysis of the clinical use of incretinbased therapies: are GLP-1 therapies safe? Diabetes Care 2013 May 6 (epub).
14. T Stulc and A Sedo. Inhibition of multifunctional dipeptidyl peptidase- IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010; 88:125.